Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis
- PMID: 19670217
- DOI: 10.1002/path.2574
Does chromosome 17 centromere copy number predict polysomy in breast cancer? A fluorescence in situ hybridization and microarray-based CGH analysis
Abstract
Approximately 8% of breast cancers show increased copy numbers of chromosome 17 centromere (CEP17) by fluorescence in situ hybridization (FISH) (ie average CEP17 >3.0 per nucleus). Currently, this pattern is believed to represent polysomy of chromosome 17. HER2-amplified cancers have been shown to harbour complex patterns of genetic aberrations of chromosome 17, in particular involving its long arm. We hypothesized that aberrant copy numbers of CEP17 in FISH assays may not necessarily represent true chromosome 17 polysomy. Eighteen randomly selected CEP17 polysomic cases and a control group of ten CEP17 disomic cases, as defined by dual-colour FISH, were studied by microarray-based comparative genomic hybridization (aCGH), which was performed on microdissected samples using a 32K tiling-path bacterial artificial chromosome microarray platform. Additional FISH probes were employed for SMS (17p11.2) and RARA (17q21.2) genes, as references for chromosome 17 copy number. Microarray-based comparative genomic hybridization revealed that 11 out of the 18 polysomic cases harboured gains of 17q with involvement of the centromere, one displayed 17q gain sparing the centromeric region, and only one could be defined as polysomic. The remaining five cases displayed amplification of the centromeric region. Among these, one case, showing score 2+ by immunohistochemistry and 8.5 HER2 mean copy number, was classified as not amplified by HER2/CEP17 ratio and as amplified by HER2/SMS ratio. Our results suggest that true chromosome 17 polysomy is likely to be a rare event in breast cancer and that CEP17 copy number greater than 3.0 in FISH analysis is frequently related to gain or amplification of the centromeric region. Larger studies investigating the genetic profiles of CEP17 polysomic cases are warranted.
Comment in
-
Be precise! The need to consider the mechanisms for CEP17 copy number changes in breast cancer.J Pathol. 2009 Sep;219(1):1-2. doi: 10.1002/path.2593. J Pathol. 2009. PMID: 19670216
Similar articles
-
Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer.Breast Cancer Res Treat. 2012 Apr;132(3):925-35. doi: 10.1007/s10549-011-1642-8. Epub 2011 Jun 23. Breast Cancer Res Treat. 2012. PMID: 21698407
-
Absence of chromosome 17 polysomy in breast cancer: analysis by CEP17 chromogenic in situ hybridization and multiplex ligation-dependent probe amplification.Breast Cancer Res Treat. 2010 Feb;120(1):1-7. doi: 10.1007/s10549-009-0539-2. Epub 2009 Sep 18. Breast Cancer Res Treat. 2010. PMID: 19760503
-
Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy.J Clin Oncol. 2011 Nov 1;29(31):4168-74. doi: 10.1200/JCO.2011.36.0107. Epub 2011 Sep 26. J Clin Oncol. 2011. PMID: 21947821
-
HER2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity.Mod Pathol. 2014 Jan;27(1):4-18. doi: 10.1038/modpathol.2013.103. Epub 2013 Jun 28. Mod Pathol. 2014. PMID: 23807776 Review.
-
The important molecular markers on chromosome 17 and their clinical impact in breast cancer.Int J Mol Sci. 2011;12(9):5672-83. doi: 10.3390/ijms12095672. Epub 2011 Sep 5. Int J Mol Sci. 2011. PMID: 22016618 Free PMC article. Review.
Cited by
-
Digital PCR quantification of ultrahigh ERBB2 copy number identifies poor breast cancer survival after trastuzumab.NPJ Breast Cancer. 2024 Feb 19;10(1):14. doi: 10.1038/s41523-024-00621-x. NPJ Breast Cancer. 2024. PMID: 38374091 Free PMC article.
-
HER2 Low Breast Cancer: A New Subtype or a Trojan for Cytotoxic Drug Delivery?Int J Mol Sci. 2023 May 4;24(9):8206. doi: 10.3390/ijms24098206. Int J Mol Sci. 2023. PMID: 37175916 Free PMC article. Review.
-
Loss of HER2 in breast cancer: biological mechanisms and technical pitfalls.Cancer Drug Resist. 2022 Oct 20;5(4):971-980. doi: 10.20517/cdr.2022.55. eCollection 2022. Cancer Drug Resist. 2022. PMID: 36627895 Free PMC article.
-
Updates on breast biomarkers.Virchows Arch. 2022 Jan;480(1):163-176. doi: 10.1007/s00428-022-03267-x. Epub 2022 Jan 14. Virchows Arch. 2022. PMID: 35029776 Review.
-
Characteristics of HER2-negative breast cancers with FISH-equivocal status according to 2018 ASCO/CAP guideline.Diagn Pathol. 2022 Jan 7;17(1):5. doi: 10.1186/s13000-021-01187-z. Diagn Pathol. 2022. PMID: 34996485 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous